Therapeutic drug monitoring of new formulation Kaletra in pregnancy

doi:10.1186/1758-2652-11-S1-P199

Journal of the International AIDS Society

Volume 11
Suppl 1

Viewing options:

Abstract
Full text
PDF (137KB)

Related literature:

Articles citing this article
on Google Scholar
Other articles by authors
on Google Scholar

Jackson V
Else LJ
Khoo SH
Gibbons SE
Brennan M
Connor EO
Boyle N
Fleming C
Coulter-Smith S
Lambert J

on PubMed

Jackson V
Else LJ
Khoo SH
Gibbons SE
Brennan M
Connor EO
Boyle N
Fleming C
Coulter-Smith S
Lambert J
Related articles/pages
on Google

on Google Scholar

Tools:

Post to:

This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Poster presentation

Therapeutic drug monitoring of new formulation Kaletra in pregnancy

V Jackson¹, LJ Else², SH Khoo², SE Gibbons², M Brennan¹, EO Connor³, N Boyle⁴, C Fleming⁴, S Coulter-Smith¹ and J Lambert⁵

¹The Rotunda Hospital, Dublin, Ireland

²Department of Pharmacology, University of Liverpool, Liverpool, UK

³The Mater Misericordiae University Hospital, Dublin, Ireland

⁴University College Hospital Galway, Galway, Ireland

⁵The Rotunda Hospital, The Mater Misericordiae University Hospital and University College Dublin, Dublin, Ireland

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):P199doi:10.1186/1758-2652-11-S1-P199


Published:	10 November 2008

First paragraph (this article has no abstract)

The new LPV/r tablet formulation has significant patient benefits over the old LPV/r SGC, including a lack of food/fluid restrictions, no need for refrigeration and a reduced daily pill count. However, like many antiretroviral drugs, the pharmacokinetics of the new LPV/r tablet during pregnancy is poorly understood. Here we report total and unbound LPV plasma concentrations during pregnancy and at post-partum.